EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine–immune interactions
2001
EBAG9/RCAS1 in Breast Cancer
Sample size: 91
publication
Evidence: moderate
Author Information
Author(s): Suzuki T, Inoue S, Kawabata W, Akahira J, Moriya T, Tsuchiya F, Ogawa S, Muramatsu M, Sasano H
Primary Institution: Tohoku University School of Medicine
Hypothesis
Is EBAG9/RCAS1 involved in endocrine–immune interactions in human breast carcinomas?
Conclusion
EBAG9 is produced via estrogen receptors in carcinoma cells and may inhibit T lymphocyte infiltration.
Supporting Evidence
- EBAG9 was detected in 90.1% of invasive ductal carcinomas.
- EBAG9 immunoreactivity was significantly associated with estrogen receptor α labelling index.
- EBAG9 was inversely associated with the degree of intratumoural infiltration of mononuclear cells.
Takeaway
This study found that a protein called EBAG9 is linked to breast cancer and might help cancer cells avoid the immune system.
Methodology
The study used immunohistochemistry and RT-PCR to examine EBAG9/RCAS1 expression in breast carcinomas.
Statistical Information
P-Value
0.0081
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website